Monopar Therapeutics Inc. (NASDAQ:MNPR) Sees Significant Growth in Short Interest

Monopar Therapeutics Inc. (NASDAQ:MNPR) was the recipient of a significant growth in short interest during the month of February. As of February 28th, there was short interest totalling 51,300 shares, a growth of 57.8% from the February 13th total of 32,500 shares. Approximately 1.3% of the company’s shares are short sold. Based on an average daily volume of 66,900 shares, the short-interest ratio is presently 0.8 days.

Institutional Trading of Monopar Therapeutics

Several institutional investors have recently added to or reduced their stakes in MNPR. JPMorgan Chase & Co. acquired a new stake in Monopar Therapeutics in the fourth quarter valued at $45,000. Geode Capital Management LLC raised its holdings in shares of Monopar Therapeutics by 174.4% during the fourth quarter. Geode Capital Management LLC now owns 38,596 shares of the company’s stock worth $849,000 after purchasing an additional 24,530 shares during the period. ADAR1 Capital Management LLC acquired a new stake in shares of Monopar Therapeutics during the fourth quarter worth $2,861,000. Point72 Asset Management L.P. acquired a new stake in shares of Monopar Therapeutics during the fourth quarter worth $3,694,000. Finally, RA Capital Management L.P. acquired a new stake in shares of Monopar Therapeutics during the fourth quarter worth $11,247,000. 1.83% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have issued reports on MNPR. Piper Sandler began coverage on shares of Monopar Therapeutics in a research note on Friday, January 10th. They set an “overweight” rating and a $72.00 price objective for the company. HC Wainwright upped their target price on shares of Monopar Therapeutics from $22.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, January 22nd.

Monopar Therapeutics Price Performance

MNPR traded up $0.26 during trading on Friday, hitting $29.75. The company had a trading volume of 20,431 shares, compared to its average volume of 361,716. The company has a market cap of $181.53 million, a PE ratio of -15.10 and a beta of 1.18. The business has a 50-day moving average of $35.77 and a 200-day moving average of $21.41. Monopar Therapeutics has a 1-year low of $1.72 and a 1-year high of $54.30.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.